Professor Bill Greenhalf is the scientific lead for the Liverpool Experimental Cancer Medicine Centre (LECMC)  and the European Registry of Hereditary Pancreatitis and Familial Pancreatic Cancer (EUROPAC). He is the Director of the Liverpool Good Clinical Practice Laboratory Facility (GCPLab) and the 2nd year assessment lead for Liverpool’s MBChB. He is also the Institutional lead for the UK Reproducibility Network (UKRN). His research focuses on pancreatic cancer and he was the president of the Pancreatic Society of Great Britain and Ireland (PSGBI) in 2019. His research has led to the introduction of the UK’s largest research surveillance program for pancreatic cancer[1] and he led on the development of international guidelines for pancreatic cancer surveillance in chronic pancreatitis[2]. He has also published extensively on therapeutic biomarkers for pancreatic cancer[3]. His lab also carries out basic research on the molecular pathogenesis of the disease[4]. During the COVID-19 crisis he directed his research towards this disease[5] and maintains an interest in SARS-CoV2 and the consequences of long covid.